Vitamin D receptor activation and cardiovascular disease
|
|
- Jocelyn Gaines
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2012) 27 (Supple 4): iv17 iv21 doi: /ndt/gfs534 Full Review Vitamin D receptor activation and cardiovascular disease Emilio Gonzalez-Parra 1, Jorge Rojas-Rivera 1, Jose Tuñón 2, Manuel Praga 3, Alberto Ortiz 1 and Jesus Egido 1 1 Division of Nephrology and Hypertension, IIS Fundación Jiménez Díaz Autonoma University and FRIAT, Madrid, Spain, 2 Division of Cardiology, Autonoma University and FRIAT, Madrid, Spain and 3 Division of Nephrology, Hospital 12 de Octubre, Madrid, Spain Correspondence and offprint requests to: Jesús Egido; jegido@fjd.es Abstract Vitamin D has been recently associated with several renal, cardiovascular and inflammatory diseases, beyond mineral metabolism and bone health. This is due in part to widespread expression of vitamin D receptor (VDR) on tissues and cells such as heart, kidney, immune cells, brain and muscle. In chronic kidney disease (CKD) and other chronic disorders, vitamin D deficiency [serum 25(OH)D <20 ng/ml] is very common and is associated with adverse outcomes. Paricalcitol, a selective activator of VDR, has demonstrated in several experimental and clinical studies of diabetic and non-diabetic CKD a favourable profile compared to other VDR activators, alone or as add-on to standard therapy. These beneficial effects are mediated by different actions such as reduction of oxidative stress, inflammation, downregulation of cardiac and renal renin expression, downregulation of calcifying genes and direct vascular protective effects. Furthermore, paricalcitol beneficial effects may be independent of baseline serum parathyroid hormone (PTH), calcium and phosphate levels. These benefits should be confirmed in large and well-designed ongoing clinical trials. Vitamin D in chronic kidney disease patients Vitamin D is essential not only in mineral metabolism homeostasis, but also to human health. Several epidemiological studies have shown an important association between vitamin D deficiency and cardiovascular mortality, hypertension, neoplasms and immunity disorders. The nuclear vitamin D receptor (VDR) is present in many human tissues. VDR is most highly expressed in small intestine, colon, kidney, bone and skin, but also in other tissues and cell types like the vascular system, endocrine organs, immune system, brain and muscle [1]. Vitamin D has numerous non-calcemic functions [2]. Around 80% of vitamin D functions are autocrine/paracrine effects independent of endocrine control of mineral metabolism. The remaining 20% are endocrine functions, such as actions on the intestine, bone and parathyroid glands. One of the most important autocrine effects of VDR activation is on the cardiovascular system and has been associated with reduced cardiovascular risk. Chronic kidney disease (CKD) patients have high rates of cardiovascular mortality, probably in part due to this vitamin D deficiency. Furthermore, several studies have suggested that therapy of vitamin D deficiency reduces this high mortality. However, an excessive treatment could also increase the cardiovascular risk [3]. The vitamin D status in CKD patients is assessed by measuring 25-hydroxy-vitamin D [25(OH)D] levels in blood. The values between 20 and 30 ng/ml are considered insufficient, and <20 ng/ml, deficient [4]. There is a high prevalence of vitamin D deficiency in healthy and ill population [4].Vitamin D deficiency and insufficiency are also very common in CKD patients, especially in winter [5]. Other causes contributing to vitamin D deficiency include lower intake of vitamin D, especially vegetables, less sun exposure and upregulated 25(OH)D- 24-hydroxylase [6]. In CKD, vitamin D supplementation needs active VDR activators (calcitriol or paricalcitol). However, correction of abnormal uptake of 25(OH)D by monocyte 1-hydroxylase and increased renal 25(OH)D uptake by megalin are also desirable. Calcidiol, calcitriol or paricalcitol can upregulate 25(OH)D-24-hydroxylase, thereby limiting local calcitriol production for autocrine/ paracrine VDR activation [7]. Low levels of serum vitamin D have been associated with increased cardiovascular risk, hypertension and mortality in haemodialysis patients [8 11]. Correction of vitamin D deficiency Clinical and animal studies support the existence of biphasic cardiovascular effects of vitamin D, in which lower doses suppress and higher doses increase the cardiovascular risk [8]. The therapeutic window is probably narrower than suggested, as an altered vitamin D metabolism in CKD patients sensitizes them to toxicity [12, 13]. Replacement with ergocalciferol or 25-OH-vitamin D increases 25(OH)D levels in most, but not all patients [14]. The reasons for this variability are not well known, The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oup.com
2 iv18 but differential 25-hydroxyvitamin D-24-hydroxylase activity and FGF-23 may contribute [15]. A meta-analysis of prospective randomized clinical trials from 1996 to 2009 suggested that vitamin D supplementation at moderate to high doses may reduce the cardiovascular disease risk [16]. A nutritional trial currently is randomizing healthy older men and women throughout the USA to receive either 2000 IU of vitamin D3 (cholecalciferol) per day or placebo for 5 years for primary prevention of heart disease, stroke and cancer. The treatment with an active VDR activator overrides the increase in mortality associated with a deficit of 25(OH) vitamin D [17]. VDR activation in CKD: the role of paricalcitol There are different treatments to activate the VDR. Calcitriol is the endogenous active molecule. Other molecules need to be activated in kidney, liver or both to be transformed into calcitriol as vitamin D2 or ergocaciferol, 1-hydroxy-vitamin D2 (doxercalciferol), vitamin D3 (cholecalciferol), [25(OH) D3] (calcidiol) and 1-hydroxy-vitamin D3 (alfacalcidol). Other active molecules that do not require VDR transformation to activate the VDR, called selective activators, are paricalcitol (19-nor-1,25-dihydroxy-vitamin D2) and maxacalcitol (22-oxacalcitriol). There are clinical recommendations on treatment with nutritional vitamin D in the general population or patients with CKD. The Institute of Medicine recommended target 25(OH)D levels >20 ng/ml [18]. The recommended daily intake under 70 years is 600 IU/day of vitamin D2 or D3, while over 70 should be 800 IU/day. The KDIGO 2009 guidelines recommend to measure and treat vitamin D insufficiency in patients with CKD stages 3 5, but there are no recommendations on vitamin D by cardiological societies, although an expert panel recommended to assess vitamin D status and to treat vitamin D deficiency in all patients at high cardiovascular risk. Active vitamin D is necessary for 25(OH)D internalization and activation. For this reason, the exclusive treatment with 25(OH)D may not be sufficient to activate the VDR in the absence of endogenous calcitriol [7]. In CKD, there are guidelines on the use of active vitamin D for the treatment of secondary hyperparathyroidism, but little guidance outside this specific situation. The selection of an active molecule and the dose to be used are debated, but many observational studies have shown that paricalcitol has a better protective effect on cardiovascular risk than calcitriol [19]. There are doubts about the indication of these molecules in patients with PTH <150 ng/ml. A particular worry in these patients is the risk of developing adynamic bone and increased vascular calcification. The following paragraphs discuss the beneficial effects of paricalcitol versus calcitriol on the cardiovascular system, even in patients with low PTH. Survival In observational studies, VDR activators were associated with improved survival and the effects were more marked for paricalcitol [19 25]. The increased mortality of CKD patients with serum 25(OH)D <30 ng/ml is not observed in patients treated with calcitriol or paricalcitol [24]. The improved survival in patients treated with paricalcitol has been observed at any PTH level, including patients with very high PTH [25]. For several decades, VDR activators have been used to treat secondary hyperparathyroidism (PTH levels >300 pg/dl). In addition, decreased mortality has also been observed in paricalcitol-treated CKD patients with PTH <150 ng/ml [26]. Vascular effects and the heart E. Gonzalez-Parra et al. Experimental studies have shown that paricalcitol, but not calcitriol, protects from vascular calcifications in uremic rats [27, 28]. Paricalcitol reduces the expression of genes involved in atherosclerosis: vascular cell growth, thrombus formation, fibrinolysis and endothelial regenerationrelated genes [29]. Paricalcitol also mitigates disturbed aortic gene expression induced by uremia [30]. In rats, paricalcitol prevents the progression of left ventricular hypertrophy (LVH) and the development of heart failure [31 34]. It also decreases heart renin expression [33]. The combination of losartan and paricalcitol is able to maintain cardiac renin levels, which rise on monotherapy with losartan, adding effects in reducing LVH. Paricalcitol also decreases LVH and fibrosis secondary to uremia [34]. Despite these encouraging preclinical data, in the PRIMO randomized placebo-controlled trial, paricalcitol failed to reduce LVH in CKD patients with moderate LVH and ipth pg/ml [35]. Reduction in LVH was the primary endpoint of the study. Paricalcitol reduced BNP levels, left auricular volume and hospitalization for cardiovascular reasons. Most patients were treated with renin angiotensin aldosterone system (RAAS) inhibitors. Potential renoprotective effects of vitamin D receptor activation Paricalcitol has demonstrated potential renoprotective effects in experimental animals [33, 42 44]. It reduced fibrosis following unilateral ureteral obstruction [36], decreased proteinuria as add-on to RAAS blockers in diabetic nephropathy [37] and was nephroprotective in models of cyclosporine toxicity [38]. An antiproteinuric effect of paricalcitol has been described in human CKD, especially in diabetic kidney disease [39]. However, the largest trial to date, the VITAL trial, missed significance in its primary endpoint [39] and the results were confused by widespread vitamin D insufficiency among participants [40]. Clearly, we need better designed clinical trials to determine the true role of paricalcitol and other VDR activators in these conditions. An ongoing Spanish multi-center, open-label, randomized clinical trial (the PALIFE study) [41] will randomize 236 patients with diabetic and non-diabetic CKD to paricalcitol plus standard care or standard care only, to assess the effect on albuminuria, systemic and renal inflammation,
3 Vitamin D receptor activation and cardiovascular disease renal fibrosis and endothelial function, among others. Importantly, this study will only recruit patients with serum 25(OH)D levels >20 ng/ml. Endpoints will be analysed at 6 months (end of treatment period) and after 2 months of wash-out (total follow-up 8 months). A recent meta-analysis of nine studies comparing paricalcitol with placebo concluded that paricalcitol suppressed serum ipth and reduced proteinuria [42]. Potential mechanisms involved in the beneficial effects of VDR activation on CVD Several mechanisms may contribute to the differential survival between calcitriol and paricalcitol in CKD [19]. Thus, compared with those not treated with a VDR activator, the use of paricalcitol appears to reduce mortality regardless of the dose used [25] and at any level of serum PTH [23]. Dialysis patients with PTH <150 pg/ml have increased cardiovascular risk and decreased survival, probably related to adynamic bone and vascular calcification [43]. Patients treated with paricalcitol and PTH <150 pg/ml have better survival than those treated with iv19 calcitriol or not receiving vitamin D [26]. The survival advantage in patients treated with paricalcitol was independent of calcium, phosphorus, PTH, age and albumin [26]. Specific paricalcitol effects such as reduced expression of calcifying genes, oxidative stress, inflammation, intestinal absorption of calcium and phosphorus and calcium release from bone may modulate cardiovascular biology and vascular calcification. Reduced expression of calcifying genes When compared with other VDR activators, paricalcitol may directly protect from vascular calcification, as demonstrated in cells and in animal models [28, 44, 45]. This protective effect would be useful even in patients with increased susceptibility to vascular calcification, such as inflammed patients and those with adynamic bone disease [28]. The different effects of VDR activators on vascular calcification cannot be totally accounted for by the differences in calcium-phosphate product and direct effects of paricalcitol on the vascular wall have been observed [46]. 1-Hydroxyvitamin D 2 (doxercalciferol) or calcitriol increased Runx2 (Cbfα1) and osteocalcin mrna expression in the aorta, independent of the Fig. 1. Mechanisms of cardioprotection and nephroprotection of paricacitol with experimental and supporting clinical evidence. BNP, brain natriuretic peptide; Ca, calcium; CKD, chronic kidney disease; CV, cardiovascular; HD, haemodialysis; LVH, left ventricular hypertrophy; P, phosphorus; PD, peritoneal dialysis; RAAS, renin angiotensin aldosterone system; RCT, randomized clinical trial; TX, renal transplant; VDR, vitamin D receptor.
4 iv20 calcium-phosphate product, whereas paricalcitol did not. Runx2 (Cbfα1) and osteocalcin modulate skeletal mineralization and vascular calcification [46, 47]. Runx2 promotes differentiation into an osteoblast or bone producing cell. Reduced oxidative stress and inflammation In animal models, paricalcitol reduces inflammation and oxidative stress and prevents plaque formation in ApoE / mice [48]. In haemodialysis patients, paricalcitol decreases interleukins 1(IL1), IL6 and tumor necrosis factor [49]. VDR activation reduced kidney inflammatory molecules and limited the profibrogenic and proinflammatory response of kidney cells to metabolic abnormalities including hyperglycemia [49, 50], and decreased renin activity in cardiomyocytes [32]. Reduced intestinal absorption of calcium and phosphorus In rats, paricalcitol is slightly less potent than doxercalciferol (0.6:1) in suppressing serum PTH, but is 5- to 10-fold less calcemic and phosphatemic [45]. In haemodialysis patients, intestinal calcium absorption was 14% lower on paricalcitol than on calcitriol [51]. Paricalcitol resulted in lower levels of intestinal calbindin, a protein involved in intestinal calcium transport, than calcitriol [52]. This lower absorption of calcium may be important to prevent vascular calcification: given that CKD bone has a reduced ability to bind calcium, absorbed calcium contributes to vascular calcification even in the absence of changes in serum calcium level [43]. Decreased calcium release from bone Release of calcium from bone is 10 times lower in rats treated with paricalcitol than with calcitriol [53]. Paricalcitol increased the bone turnover, increasing the osteoclastic activity less than calcitriol, while increasing the osteoclast activity more than calcitriol, leading to an increased bone volume, trabecular thickness and osteoid surface [54]. Conclusion In observational studies, activation of the VDR is associated with lower cardiovascular risk and improved survival. The beneficial effects of VDR activation go far beyond endocrine functions of vitamin D, such as control of secondary hyperparathyroidism. Supplementation with 25 (OH)D is not sufficient in the absence of active metabolites of vitamin D. Paricalcitol has demonstrated beneficial effects in both experimental and clinical studies, compared with calcitriol. The activation of specific genes by paricalcitol protects the vascular system from calcification, reduces cardiac and renal renin, decreases inflammation and has renoprotective effects, decreasing proteinuria. Taken together, these results provide a biological basis for the observed reduction of cardiovascular mortality in renal patients, including patients with PTH <150 pg/ml or with hyperphosphatemia (Figure 1). Before paricalcitol can be considered as the first choice for cardiovascular protection in CKD patients as it is for the control of secondary hyperparathyroidism, the beneficial effects of this drug, demonstrated in experimental studies and small clinical trials, must be confirmed in ongoing and future studies Funding. Some of the work cited in this review are granted by the following agencies: ISC III (PI10/00072), RECAVA (RD06/0014/0035;) y European Network (HEALTH F ), Euro Salud EUS cvremod (091100) and Fundacion Lilly to J.E. And ISCIII and FEDER funds PS09/00447, ISCIII-RETIC REDinREN/ RD06/0016, Comunidad de Madrid/CIFRA, S2010/BMD-2378, Programa Intensificación Actividad Investigadora (ISCIII/Agencia Laín- Entralgo/CM) to A.O. Conflict of interest statement. E.G.P., J.R.R., M.P., A.O. and J.E. are the members of the PALIFE steering committee, a clinical trial assessing the effects of paricalcitol on CKD. References E. Gonzalez-Parra et al. 1. Maalouf NM. The noncalciotropic actions of vitamin D: recent clinical developments. Curr Opin Nephrol Hypertens 2008; 17: Rojas-Rivera J, De La Piedra C, Ramos A et al. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: Lee JH, O Keefe JH, Bell D et al. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? JAm Coll Cardiol 2008; 52: González-Parra E, Avila PJ, Mahillo-Fernández I et al. High prevalence of winter 25-hydroxyvitamin D deficiency despite supplementation according to guidelines for hemodialysis patients. Clin Exp Nephrol [Epub ahead of print] 6. Masuda S, Byford V, Arabian A et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005; 146: Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: Forman JP, Giovannucci E, Holmes MD et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: Gracia-Iguacel C, Gallar P, Qureshi AR et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010; 20: Navaneethan SD, Schold JD, Arrigain S et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis 2011; 58: Drueke TB, Massy ZA. Role of vitamin D in vascular calcification: bad guy or good guy? Nephrol Dial Transplant 2012; 27: Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol 2010; 25: Al-Aly Z, Qazi RA, González EA et al. Changes in serum 25- hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50: Hu P, Xuan Q, Hu B et al. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. Int J Biol Sci 2012; 8: Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152:
5 Vitamin D receptor activation and cardiovascular disease 17. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: Rosen CJ, Gallagher JC. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011; 14: Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: Naves Diaz M, Alvarez Hernandez D, Passlick-Deetjen J et al. Oral vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: Dobnig H, Pilz S, Scharnagl H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: Lee GH, Benner D, Regidor DL et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: Wolf M, Betancourt J, Chang Y et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: Cozzolino M, Brancaccio D, Messa G et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <150 pg/ml: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: Guerrero F, Montes de Oca A, Aguilera-Tejero E et al. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: Wu-Wong JR, Nakane M, Ma J et al. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006; 186: Wu-Wong JR, Nakane M, Ma J et al. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem 2007; 100: Bae S, Yalamarti B, Ke Q et al. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc Res 2011; 91: Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl saltsensitive animals. Proc Natl Acad Sci USA 2007; 104: Kong J, Kim GH, Wei M et al. Therapeutic effects of vitamin D analogs on cardiac hyperthrophy in spontaneously hypertensive rats. Am J Phatol 2010; 177: Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121: Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: Tan X, Li Y, Liou Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. JAmSocNephrol2006; 14: Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: Park JW, Bae EH, Kim IJ et al. Paricalcitol attenuates cyclosporineinduced kidney injury in rats. Kidney Int 2010; 77: De Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: Ortiz A, Sanchez Niño MD, Rojas JE et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2011; 377: Egido J, Rojas-Rivera J, Praga M et al. The PALIFE study. htpp//: Cheng J, Zhang W, Zhang X et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012; 7: London GM, Marchais SJ, Guérin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: Cardús A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: Noonan W, Koch K, Nakane M et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008; 23: Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: Becker LE, Koleganova N, Piecha G et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011; 300: F772 F Husain K, Suárez E, Isidro A et al. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010; 32: Sanchez-Niño MD, Bozic M, Córdoba-Lanús E et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302: F647 F Sanchez-Niño MD, Sanz AB, Carrasco S et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 2011; 26: Lund R, Tian J, Melnick J et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Nephrol Dial Transplant 2006; 21: Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor- 1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315 F Nakane M, Fey TA, Dixon DB et al. Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: Received for publication: ; Accepted in revised form: iv21
02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationUremic Cardiomyopathy with a focus on the role of α-klotho and FGF23
Uremic Cardiomyopathy with a focus on the role of α-klotho and FGF23 Marc G Vervloet, MD, PhD, FERA VU university medical center Amsterdam, The Netherlands Disclosures Scientific support AbbVie, Amgen,
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationEffective Treatment Strategies to Delay the Progression of Renal Disease in CKD
Effective Treatment Strategies to Delay the Progression of Renal Disease in CKD Csaba P Kovesdy, MD FASN Memphis VA Medical Center, Memphis TN University of Tennessee, Memphis TN Vitamin D Metabolic acidosis
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationKidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation
review http://www.kidney-international.org & 2011 International Society of Nephrology Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation Adriana S. Dusso
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationVitamin D & Cardiovascular Disease
Vitamin D & Cardiovascular Disease Disclosures None Vitamin D Objectives: Discuss the basics of vitamin D metabolism Discuss the role of vitamin D deficiency in the development of coronary disease Review
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationJ.Bacchetta has documented that she has received grants for research activities from Amgen, Crinex, Sandoz.
J.Bacchetta has documented that she has received grants for research activities from Amgen, Crinex, Sandoz. Epidemiological, immune and metabolic aspects of vitamin D in CKD Justine Bacchetta, MD, PhD
More informationErgocalciferol and Cholecalciferol in CKD
In Practice Ergocalciferol and Cholecalciferol in CKD Sagar U. Nigwekar, MD, 1,2 Ishir Bhan, MD, MPH, 1 and Ravi Thadhani, MD, MPH 1 The development of chronic kidney disease (CKD) is accompanied by a
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationThe Role of Vitamin D in Heart Disease. Janet Long, MSN, ACNP, CLS, FAHA, FNLA Cardiovascular Institute Rhode Island Hospital and The Miriam Hospital
The Role of Vitamin D in Heart Disease Janet Long, MSN, ACNP, CLS, FAHA, FNLA Cardiovascular Institute Rhode Island Hospital and The Miriam Hospital None Conflict of Interest What is Vitamin D Produced
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationRENAL GRAND ROUNDS. Vitamin D- Beyond the bone. Dr Krishna Pakkivenkata. 9 th April 2010.
RENAL GRAND ROUNDS Vitamin D- Beyond the bone Dr Krishna Pakkivenkata. 9 th April 2010. Brief history Secosteroid. 1920 s-exposure to sunlight prevented rickets. 1936- structure of Vit D was discovered.
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationChronic kidney disease, hypovitaminosis D, and mortality in the United States
http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 931 Chronic kidney disease, hypovitaminosis D, and mortality in the United States Rajnish Mehrotra
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationFGF23 (and Klotho): what s new? Brief introduction to FGF23. Introduction to FGF23. FGF23: phosphorylation pathways. FGF23: phosphorylation pathways
(and Klotho): what s new? Brief introduction to Justine Bacchetta, MD, PhD Reference Center for Rare Renal Diseases Long Beach, CA, 2017 Calcium and phosphate metabolism 1-25 vitamin D Introduction to
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationSteroid hormone vitamin D: Implications for cardiovascular disease Circulation research. 2018; 122:
Steroid hormone vitamin D: Implications for cardiovascular disease Circulation research. 2018; 122:1576-1585 November 20, 2010: Canadian and US government request the Institute of Medicine to provide a
More informationVitamin D and Cardiovascular Disease
Vitamin D and Cardiovascular Disease Carrie W. Nemerovski, Pharm.D., Michael P. Dorsch, Pharm.D., Robert U. Simpson, Ph.D., Henry G. Bone, M.D., Keith D. Aaronson, M.D., and Barry E. Bleske, Pharm.D.,
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationA Randomised Clinical Study of Alfacalcidol and Paricalcitol
PHD THESIS DANISH MEDICAL JOURNAL A Randomised Clinical Study of Alfacalcidol and Paricalcitol Two vitamin D analogs for treatment of secondary hyperparathyroidism in chronic hemodialysis patients Ditte
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationVitamin D deficiency and heart disease
http://www.kidney-international.org & 2011 International Society of Nephrology Vitamin D deficiency and heart disease Stefan Pilz 1,2, Andreas Tomaschitz 1, Christiane Drechsler 3 and Rudolf A. de Boer
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationSupplementary Information to Chapter 36
REVIEW ON VITAMIN-D NEW INSIGHTS Elmer Verner McCollum (1879-1967) was the first to discover the antirachitic vitamin which he named as vitamin D in the early part of 20th century (1919). He had earlier
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationVitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016
Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationImpact of serum FGF23 levels on blood pressure of patients with chronic kidney disease
European Review for Medical and Pharmacological Sciences 2018; 22: 721-725 Impact of serum FGF23 levels on blood pressure of patients with chronic kidney disease J.-X. LI, G.-Q. YU, Y.-Z. ZHUANG Department
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationKidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals
review http://www.kidney-international.org & 2010 International Society of Nephrology Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and
More informationTHE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION
THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory
More informationTreatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3 4: a preliminary study
Clinical Kidney Journal Advance Access published February 5, 2013 Clin Kidney J (2013) 0: 1 5 doi: 10.1093/ckj/sfs188 Original Article Treatment with oral paricalcitol in daily clinical practice for patients
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationNew vitamin D analogs
Kidney International, Vol. 63, Supplement 85 (2003), pp. S83 S87 New vitamin D analogs EDUARDO SLATOPOLSKY, JANE FINCH, and ALEX BROWN Renal Division, Department of Internal Medicine, Washington University
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationMineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation
review http://www.kidney-international.org & 2011 International Society of Nephrology Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin
More informationCorporate Presentation January 2013
Corporate Presentation January 2013 0 Forward-Looking Statements Certain statements and information included in this presentation are forwardlooking statements under the Private Securities Litigation Reform
More informationClass Review: Vitamin D Analogs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationVitamin D in Cattle: Calcium and Beyond. Corwin D. Nelson, Ph.D. Assistant Professor of Physiology Department of Animal Sciences
OH HO OH Vitamin D in Cattle: Calcium and Beyond Corwin D. Nelson, Ph.D. Assistant Professor of Physiology Department of Animal Sciences Seminar Outline 1. Basics of vitamin D metabolism and genomic actions
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationRaising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion
Endocrine (2018) 59:242 259 DOI 10.1007/s12020-017-1369-3 REVIEW Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion Sandro Giannini 1 Sandro Mazzaferro
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationTHEMED SECTION: ADVANCES IN NUTRITIONAL PHARMACOLOGY REVIEW Potential for vitamin D receptor agonists in the treatment of cardiovascular disease
THEMED SECTION: ADVANCES IN NUTRITIONAL PHARMACOLOGY REVIEW Potential for vitamin D receptor agonists in the treatment of cardiovascular disease JR Wu-Wong British Journal of Pharmacology (2009), 158,
More information